Indirect costs and related factors for patients with non-small cell lung cancer treated with targeted therapy in Vietnam 10.55131/jphd/2026/240120
Article Sidebar
Main Article Content
Abstract
The objective of our study was to estimate indirect costs and identify the factors affecting them. Additionally, we aimed to determine which age group impacts the component costs of the total indirect costs for non-small cell lung cancer (NSCLC) patients treated with targeted therapy. This cross-sectional descriptive study was conducted through interviews about indirect costs for one month, from October 2022 to December 2023, with 310 NSCLC patients at the Vietnam National Cancer Hospital. All indirect costs were standardized according to the Consumer Price Index (CPI) and converted to 2023 US dollars. The monthly mean total indirect costs for NSCLC patients were $96.0. The rate of caregivers' absence from work was 49%, and 37.7% of patients experienced income loss. However, the highest cost was income loss at $83.3, accounting for 86.8%, while caregivers' absence cost $10.1, accounting for 10.6% of the total indirect costs. The costs of patients’ absence and income loss were higher for patients under 60 years old (p < 0.001 for each group). Factors such as age (under 60), gender (male), and occupation (employed or unemployed) were identified as related to an increase in the total indirect costs for NSCLC patients compared to other groups (p < 0.05 for each group). Support from insurance agencies for patients’ absence and income loss is truly meaningful.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Cao W, Qin K, Li F, Chen W. Socioeconomic inequalities in cancer incidence and mortality: An analysis of GLOBOCAN 2022. Chinese Medical Journal. 2024;137(12):1407. doi:10.1097/CM9.0000000000003140
Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol. 2022;27(4):665-675. doi:10.1007/s10147-021-02108-2
Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1(1):1-16. doi: 10.1038/nrdp.2015.9
Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154. doi: 10.1016/j.lungcan.2005.06.005
Zhang X, Liu S, Liu Y, et al. Economic Burden for Lung Cancer Survivors in Urban China. International Journal of Environmental Research and Public Health. 2017;14(3):308. doi: 10.3390/ ijerph14030308
Produção G, Faria B, do Vale JW, Facin A, Carvalho M. Main challenges in the identification and measurement of indirect costs in projects: a multiple case study. Gestão & Produção. 2020;27. doi:10.1590/ 0104-530x4913
Iragorri N, de Oliveira C, Fitzgerald N, Essue B. The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review. Curr Oncol. 2021;28(2):1216-1248. doi: 10.3390/curroncol28020117
Oliveira C de, Weir S, Rangrej J, et al. The economic burden of cancer care in Canada: a population-based cost study. Canadian Medical Association Open Access Journal. 2018;6(1):E1-E10. doi:10.9778/cmajo.20170144
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165-1174. doi:10.1016/S1470-2045(13) 70442-X
Seung SJ, Hurry M, Hassan S, Walton RN, Evans WK. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol. 2019;26(2):102-107. doi:10.3747/co.26.4555
Aminuddin F, Bahari MS, Zainuddin NA, Mohd Hanafiah AN, Mohd Hassan NZA. The Direct and Indirect Costs of Cancer among the Lower-Income Group: Estimates from a Pilot and Feasibility Study. Asian Pac J Cancer Prev. 2023;24(2):489-496. doi:10.31557/APJCP.2023.24.2.489
Fautrel B, Boonen A, Wit M de, Grimm S, Joore M, Guillemin F. Cost assessment of health interventions and diseases. RMD Open. 2020;6(3): e001287. doi:10.1136/rmdopen-2020-001287
Araújo JKL, Silva LM da, Santos CA, Oliveira I da S, Fialho GM, Giglio A del. Assessment of costs related to cancer treatment. Rev Assoc Med Bras. 2020;66:1423-1430. doi: https://doi.org/10.1590/1806-9282. 66.10.1423
Yang Y, Xia Y, Su C, et al. Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China. J Cancer Res Clin Oncol. 2023;149(8):4205-4214. doi:10.1007/s00432-022-04258-w
Tran HTT, Nguyen S, Nguyen KK, et al. Lung Cancer in Vietnam. Journal of Thoracic Oncology. 2021; 16(9):1443-1448. doi:10.1016/j.jtho. 2021.06.002
Zarogoulidou V, Panagopoulou E, Papakosta D, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. Journal of Thoracic Disease. 2015;7(Suppl 1). doi: 10.3978/j.issn.2072-1439.2015.01.57
C Choong, AMM Firouz, AF Jasmin, et al. Time to care: Gender inequality, unpaid care work and time use survey. Khazanah Research Institute. Published online 2019:1-174.
Kiet PHT, Phuong PC, Chinh NV, et al. Direct medical cost of late-stage lung cancer treatment in vietnam based on big data analysis of National Social Health Insurance database 2020. JMR. 2023;172(11):210-216. doi:10.52852/tcncyh.v172i11.1882
Yoo W, Mayberry R, Bae S, Singh K, He Q, Lillard J. A Study of Effects of MultiCollinearity in the Multivariable Analysis. International journal of applied science and technology. 2014;4:9-19.
Kyriazos T, Poga M. Dealing with Multicollinearity in Factor Analysis: The Problem, Detections, and Solutions. Open Journal of Statistics. 2023;13(3):404-424. doi: 10.4236/ ojs.2023.133020
Nipp RD, Kirchhoff AC, Fair D, et al. Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2017;35(30):3474-3481. doi:10.1200/JCO.2016.71.7066
Zullig LL, Peppercorn JM, Schrag D, et al. Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. JOP. 2013; 9(6S):60s-63s. doi:10.1200/JOP. 2013.000971
Nipp RD, Zullig LL, Samsa G, et al. Coping with cancer treatment-related financial burden. JCO. 2014;32 (31_suppl):161-161. doi:10.1200/jco. 2014.32.31_suppl.161
Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710-3717. doi:10.1002/cncr.28262
Neugut AI, Subar M, Wilde ET, et al. Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer. JCO. 2011;29(18):2534-2542. doi:10.1200/JCO.2010.33.3179
Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016; 122(8):283-289. doi:10.1002/cncr. 29808
Ramsey SD, Bansal A, Fedorenko CR, et al. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. JCO. 2016;34(9):980-986. doi:10.1200/ JCO.2015.64.6620
Navaratnam S, Kliewer EV, Butler J, Demers AA, Musto G, Badiani K. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer. 2010;70(1):110-115. doi: 10.1016/j.lungcan.2010.01.012
